Hesperos Inc.

Attending the American Academy of Neurology Annual Meeting this week? Don’t miss Sandra Paulina Smieszek, Ph.D. from Vanda Pharmaceuticals as she presents exciting work on the development of VCA-894A, a novel therapeutic customized for an individual patient with a specific genetic mutation of Charcot-Marie-Tooth disease type 2S. Efficacy was demonstrated using Hesperos’ Human-on-a-Chip® neuromuscular junction model with patient-derived cells, showing significant improvements in neuromuscular function - including reduced muscle fatigue and enhanced synaptic transmission between motor neurons and skeletal muscle myotubes. The FDA has granted Orphan Drug Designation utilizing this data, and the therapeutic is expected to be administered to the patient in the near future. This represents a major milestone in precision medicine for rare diseases - especially those with no existing models. Learn more and find Dr. Smieszek’s presentation details: https://buff.ly/Orw0ckz #AANAM #PrecisionMedicine #HumanOnAChip #RareDiseases #NAMs #CMT

Hesperos Senior Scientist Kaveena Autar is presenting a poster next week at American Academy of Neurology's 2025 Annual Meeting. Her poster will cover the use of our Human-On-A-Chip models in assessing neurocognitive impairment. Dr. Autar's will be presenting at 8:00 AM PST on April 7th, and her poster will also be available for online viewing for attendees during the same time. Visit https://buff.ly/sMsspYl to learn more. Be sure to stop by and see if Dr. Autar if you're attending! #AANAM #NAMs #HumanOnAChip

Make sure you don't miss our team presenting this week at #2025SOT! Several members of our team are presenting posters, and Chief Scienst J. Hickman is co-chairing a panel, Next generation of in vitro neurotoxicology – modeling cognition-in-a-dish. See below for the full presentation list. J. Hickman, PhD: Co-chair, Next generation of in vitro neurotoxicology – modeling cognition-in-a-dish, March 19, 8:00 am J. Hickman, PhD: #L609, Differential Metabolism in Microphysiological Systems for Evaluation of Efficacy and Off-target Toxicity for the NK-1 Antagonist Tradipitant, March 19, 9:15-11:45 am Kaveena Autar, PhD: #P745, The Utilization of In Vitro, Human-on-a-Chip® Cortical Networks to Assess Neurocognitive Impairment for Drug Safety and Efficacy, March 18, 9:15-11:45 am Mridu Malik, PhD:#K569, Off-target toxicity and efficacy testing of a novel stress reliever in a multi-organ microphysiological system, March 19, 9:15-11:45 am Walker Hagan, PhD: #K571, A Human-on-a-Chip® neuromuscular junction model for the evaluation of botulinum neurotoxin potency, March 19, 9:15-11:45 am Michael Jakob Rupar: #K565, Safety Assessment of Antimalarial Therapeutic Delivery in a Human-Based Malaria-on-a-Chip® Phenotypic Disease Model, March 19, 9:15-11:45 am If you have any questions or want to follow up on a presentation, swing by booth #1071 to speak to one of our team members. #ToxExpo #NAMs #Biotech #HumanOnAChip

We are exhibiting this week at Society of Toxicology (SOT) of Toxicology's #2025SOT! Come visit us at booth #1071 to learn more about our Human-On-A-Chip technology. We also have five poster presentations throughout the week, and Hesperos Chief Scientist J. Hickman is co-chairing the "Next generation of in vitro neurotoxicology – modeling cognition-in-a-dish" symposium on 3/19 at 8:00 am. Be sure to stop by and see us if you're there! #ToxExpo #NAMs #HumanOnAChip #Biotech

An exciting new study by Vanda Pharmaceuticals, in collaboration with Hesperos researchers, was recently published in Molecular Therapy Nucleic Acids. The article explores the potential for ASO-based personalized treatment development leveraging Hesperos’ Human-on-a-Chip® technology. Our neuromuscular junction (NMJ) model played a key role in evaluating their antisense oligonucleotide (ASO) therapy designed for a patient with a rare variant of Charcot-Marie-Tooth disease type 2S (CMT2S). This research highlights the tremendous potential of ASO therapeutics in advancing personalized medicine for rare diseases! Learn more: https://buff.ly/8jy2rtu #NAMs #HumanOnAChip #CMT #CharcotMarieTooth #Biotech #RareDiseases #Neuromuscular

On January 31, Hesperos co-founder Dr. Michael Shuler will be speaking at Technology Networks' Ask Me Anything: Body-On-A-Chip live webinar. He will be answering questions on the development and applications of Human-On-A-Chip technology and sharing insights into the future of the field. Register to attend free at https://buff.ly/4jiy0EF #NAMs #HumanOnAChip #biotech

Hesperos researchers, in collaboration with the University of Central Florida (UCF), have developed a multi-organ, microphysiological acute opioid overdose and recovery (AOOR) model designed to help address the opioid crisis. This human cell-based platform replicates the physiological aspects of an overdose and recovery, allowing researchers to evaluate recovery agents like naloxone for both efficacy and off-target toxicity. The AOOR model could serve as a platform for testing other recovery agents, potentially advancing safer and more effective treatments for opioid overdose. We are proud of our team for their incredible work and dedication to finding solutions that address the opioid crisis. We also want to thank The National Institutes of Health HEAL initiative for their support on this study. Read the study and press release here: https://buff.ly/3C3M5F8 #Publication #Overdose #OrganOnAChip #HumanOnAChip #MPS #HEAL #NIH #Research #Hesperos

Hesperos Chief Scientist, J. Hickman, is speaking this week at "Advances in Developing Medical Countermeasures Against Opioids and Drug-Induced Respiratory Depression," hosted by the National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA). He will cover how we use #HumanOnAChip models to reproduce opiate overdose and recovery to better understand efficacy and off-target effects of potential therapeutics. Learn more about the meeting and other speakers here: https://buff.ly/4izkDzp #NIH #NIAID #BARDA #Overdose #Opioid #OrganOnAChip #Biotech

Join us for The 3Rs Collaborative (3RsC)'s Oncology MPS workshop tomorrow, Dec. 4, 10 am EST! Hesperos will be 1 of 9 companies presenting oncology models. This is the last of a series of webinars established by the 3RsC in collaboration with IQ-MPS. Register to watch free here: https://buff.ly/498DnBC #3Rs #3RsCollaborative #MPS #NAMS #organonachip

Hesperos Chief Scientist J. Hickman is virtually presenting today at PAGICLE Ltd's World Pharma 2024. His talk, “Human-on-a-chip systems as pre-clinical models for neurological diseases and disorders," will be at 11:10 am EST. World Pharma 2024 is a virtual gathering for the health industry professionals worldwide. Directors, scientists, professors, and research scholars are invited to share their research and discuss emerging technological trends in the pharmaceutical industry. Learn more about World Pharma 2024 and Dr. Hickman's presentation at https://buff.ly/4fg6sNF #WorldPharma2024 #NAMs #Humanonachip #Neuroscience